Want to join the conversation?
$BIIB 2Q15 Q&A: Flynn of Goldman Sachs asked a question about TECFIDERA out year trajectory in US. Tony commented that the company believes that market continues to move to orals and it has the best oral. BIIB believes that it can continue to add patients. It’s harder work at this point given where it is in the product lifecycle.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?